Heart risks in older men on enzalutamide or darolutamide
Part of Cancer, Kidney & urinary clinical trials.
This study looks at heart-related risks in older men with advanced prostate cancer who are taking enzalutamide or darolutamide. It may help doctors better understand how to manage heart health during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man diagnosed with prostate cancer.
- You are 55 years of age or older.
- Your cancer is either metastatic and still hormone-sensitive (mHSPC) or non-metastatic but no longer responding to hormone therapy (nmCRPC).
- You have taken at least two courses of enzalutamide or darolutamide.
- If you have mHSPC, your cancer should not have become resistant to hormone treatment before starting enzalutamide/darolutamide.
- For nmCRPC, there should be no sign the cancer has spread at the time you started enzalutamide/darolutamide.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a team of doctors, nurses, and other specialists can help reduce the risk of heart problems in men with prostate cancer who are on hormone therapy (ADT). It focuses on providing extra support for heart health.
This study tests different ways of giving hormone therapy to find the right dose for men with prostate cancer that has spread. It aims to help manage the disease while limiting side effects.
This study checks how men starting hormone therapy (ADT) for prostate cancer are doing with their heart health. It offers follow-up visits at the cancer center to track blood pressure and lab results, with the goal of catching any heart-related issues early.
This study looks at how levels of common prostate cancer hormone treatments (abiraterone, apalutamide, darolutamide, or enzalutamide) stay in your blood over time. By checking drug levels, doctors hope to personalize dosing to make treatment safer and more effective.
This study looks at how a special CT heart scan (CCTA) can help manage heart disease risk in men with prostate cancer who are taking hormone therapy (ADT). It may help your care team better assess heart risk, especially if you also have other heart risk factors but no current heart symptoms.
This trial tests a combination of two hormone therapies (darolutamide plus androgen deprivation therapy) given after surgery to remove the prostate, to see if it helps prevent the cancer from coming back in men with high-risk prostate cancer. The goal is to see if this treatment can keep the cancer from spreading or returning.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.